EGA
PGNX

Eagle Global Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Eagle Global Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-35,890
Closed -$220K – 408
2015
Q4 		$220K Sell
35,890
-8,980
-20% -$58.9K 0.01% 310
2015
Q3 		$257K Sell
44,870
-22,400
-33% -$172K 0.01% 294
2015
Q2 		$502K Hold
67,270
– – 0.01% 209
2015
Q1 		$402K Buy
+67,270
New +$423K 0.01% 221

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eagle Global Advisors's PGNX Position: Q1 2016 in Review

Eagle Global Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2016, closing a stake of 35,890 shares — an estimated $220K sold.

Eagle Global Advisors first reported a position in PGNX in Q1 2015 and held it in 4 quarters. The position peaked at $502K in Q2 2015. 120 funds tracked by Wall St. Rank hold PGNX as of Q1 2016.

  • Eagle Global Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
  • Eagle Global Advisors sold 35,890 Progenics Pharmaceuticals Inc shares in Q1 2016, an estimated $220K.
  • Eagle Global Advisors first reported a position in Progenics Pharmaceuticals Inc in Q1 2015 and held it in 4 quarters.
  • Eagle Global Advisors's Progenics Pharmaceuticals Inc position peaked at $502K in Q2 2015.
  • 120 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2016.

Based on Eagle Global Advisors's 13F filing for Q1 2016, filed 16 May 2016.